Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
The 2021 Dogs of the Dow are now known, and investors who may want to follow this investing strategy have got some thinking to do.
Six Dow stocks are on track to lose at least 10% of their value in 2020. Here's a look at what's happened.
One popular investment strategy, known as the Dogs of the Dow, has performed better than last year. What's ahead for the dogs in 2021?
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Merck has joined the fight against COVID-19 by acquiring OncoIummune in an all-cash transaction.
Chris Lange Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
Roughly a third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Health care is one sector that continues to draw a ton of fund manager interest, and with good reason. These five dividend-paying health care stocks are all favored by large-cap portfolio managers.
Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week trading highs and…
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may…
